%PDF-1.7
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
2017-01-25T09:03:09-05:00
2017-01-25T09:03:11-05:00
2017-01-25T09:03:11-05:00
Adobe InDesign CC 2017 (Windows)
uuid:1f01f1ec-4d71-4a8e-b83f-4480f4d703a4
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
xmp.id:6adb82af-7d88-ef4f-8197-6fdf1d0bea65
proof:pdf
xmp.iid:57cd28f7-777b-4d47-a929-396174745444
xmp.did:04be5ab5-a50c-a545-8c0c-b33e80d00a04
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
default
converted
from application/x-indesign to application/pdf
Adobe InDesign CC 2017 (Windows)
/
2017-01-25T09:03:09-05:00
application/pdf
Adobe PDF Library 15.0
False
endstream
endobj
3 0 obj
<>
endobj
5 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
6 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/Properties<>/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
18 0 obj
<>stream
BT
0 0 0 1 k
/GS0 gs
/TT0 1 Tf
7 0 0 7 60.48 22.6817 Tm
(2 )Tj
/Span<>> BDC
( )Tj
EMC
56.231 0 Td
[(Clinical Briefs in P)18.1 (rimary Care)]TJ
ET
q
0 g
/GS1 gs
0 TL/Fm0 Do
Q
BT
/T1_0 1 Tf
-0.01 Tc 7 0 0 7 40.75 373.76 Tm
(CLINICAL BRIEFS IN PRIMARY CARE)Tj
/T1_1 1 Tf
0 Tc 6 0 0 6 158.4884 373.76 Tm
(\231 )Tj
1.23 0 Td
( )Tj
-0.01 Tc -20.853 -1.167 Td
[(is published monthly by AHC Media, LLC. Copyright \251 2017)-9.9 ( )]TJ
0 -1.167 TD
[(AHC Media, LLC.)-10 ( )]TJ
/T1_2 1 Tf
8 0 0 8 40.75 349.76 Tm
(Executive Editor:)Tj
/T1_1 1 Tf
( Leslie Coplin)Tj
/T1_2 1 Tf
0 -1.25 TD
(Physician Editor:)Tj
/T1_1 1 Tf
( Stephen Brunton, MD)Tj
/T1_2 1 Tf
T*
(Assistant Editor:)Tj
/T1_1 1 Tf
( Jonathan Springston)Tj
6 0 0 6 40.75 315.76 Tm
[(This is an educational publication designed to present)-10 ( )]TJ
0 -1.167 TD
[(scientific information and opinion to health professionals,)-10 ( )]TJ
0 -1.167 TD
[(stimulate thought, and further investigation. It does not)-10 ( )]TJ
0 -1.167 TD
[(provide advice regarding medical diagnosis or treatment)-10 ( )]TJ
T*
(for any individual case. It is not intended for the layman.)Tj
0.01 Tc 0 -1.917 TD
(STATEMENT OF FINANCIAL DISCLOSURE)Tj
-0.025 Tc 0 -1.167 TD
[(To reveal any potential bias in this publication, and in)-25 ( )]TJ
-0.001 Tw T*
[(accordance with Accreditation Council for Continuing Medical)-25 ( )]TJ
0 Tw 0 -1.167 TD
[(Education guidelines, Dr. Brunton reports he is a retained)-25 ( )]TJ
0 -1.167 TD
[(consultant for Abbott Diabetes, Actavis, AstraZeneca, Becton)-25 ( )]TJ
T*
[(Dickinson, Boehringer Ingelheim, Cempra, Janssen, Lilly,)-25 ( )]TJ
0 -1.167 TD
[(Merck, Novo Nordisk, Sanofi, and Teva; he serves on the)-25 ( )]TJ
0 -1.167 TD
[(speakers bureau of AstraZeneca, Boehringer Ingelheim,)-25 ( )]TJ
T*
[(Janssen, Lilly, Novo Nordisk, and Teva. Dr. Kuritzky \(author\))-25 ( )]TJ
0 -1.167 TD
[(is a retained consultant for and on the speakers bureau of)-25 ( )]TJ
0 -1.167 TD
[(Allergan, Daiichi Sankyo, Lilly, and Lundbeck. Ms. Coplin and)-25 ( )]TJ
T*
[(Mr. Springston report no financial relationships relevant to this)-24.9 ( )]TJ
0 -1.167 TD
(field of study.)Tj
ET
/CS0 CS 1 SCN
0.25 w 4 M
/GS1 gs
36.125 45.125 165.734 338.51 re
S
/CS0 cs 0.1 scn
43.545 106.88 146.91 68.76 re
f
0.86 0.57 0 0.16 K
0.3 w 10 M
q 1 0 0 1 85.6163 146.0642 cm
0 0 m
80.087 0 l
S
Q
q 1 0 0 1 72.6205 139.0642 cm
0 0 m
42.017 0 l
S
Q
BT
0 0 0 1 k
/GS0 gs
/T1_2 1 Tf
0.05 Tc 8 0 0 8 48.0448 163.9401 Tm
[(SUBSCRIBER INFORMA)92 (TION)]TJ
-0.01 Tc 7 0 0 7 48.0448 153.6641 Tm
(Customer Service: \(800\) 688-2421)Tj
/T1_1 1 Tf
-0.025 Tc 6 0 0 6 48.0448 146.6641 Tm
(Email Address:)Tj
0.86 0.57 0 0.16 k
/GS1 gs
( jspringston@reliaslearning.com)Tj
0 0 0 1 k
/GS0 gs
-0.01 Tc 0.01 Tw 0 -1.167 TD
(Website: )Tj
0.86 0.57 0 0.16 k
/GS1 gs
4.096 0 Td
(AHCMedia.com)Tj
0 0 0 1 k
/GS0 gs
0 Tw -4.096 -1.917 Td
[(Address Correspondence to: AHC Media, One)-10 ( )]TJ
T*
[(Atlanta Plaza, 950 East Paces Ferry Road NE, Suite)-10 ( )]TJ
T*
[(2850, Atlanta, GA 30326.)-10 ( )]TJ
ET
/PlacedGraphic /MC0 BDC
EMC
q
81.64 55.558 70.72 32.442 re
W n
/GS1 gs
q 1 0 0 1 88.9838 74.8133 cm
0 0 m
-0.027 0 l
-0.163 -0.531 -0.313 -1.171 -0.463 -1.715 c
-1.171 -3.975 l
1.184 -3.975 l
0.463 -1.715 l
0.286 -1.157 0.136 -0.531 0 0 c
f
Q
q 1 0 0 1 107.4452 68.2239 cm
0 0 m
0.667 0 1.375 0.136 1.824 0.327 c
2.097 -0.994 l
1.702 -1.184 0.831 -1.402 -0.286 -1.402 c
-3.199 -1.402 -4.969 0.422 -4.969 3.227 c
-4.969 6.249 -2.859 8.073 -0.054 8.073 c
1.048 8.073 1.824 7.842 2.165 7.665 c
1.811 6.331 l
1.375 6.521 0.762 6.685 0.014 6.685 c
-1.852 6.685 -3.199 5.514 -3.199 3.308 c
-3.199 1.28 -2.028 0 0 0 c
-6.127 -1.252 m
-7.801 -1.252 l
-7.801 2.791 l
-11.681 2.791 l
-11.681 -1.252 l
-13.356 -1.252 l
-13.356 7.924 l
-11.681 7.924 l
-11.681 4.248 l
-7.801 4.248 l
-7.801 7.924 l
-6.127 7.924 l
h
-16.174 -1.252 m
-17.005 1.348 l
-19.905 1.348 l
-20.694 -1.252 l
-22.423 -1.252 l
-19.483 7.924 l
-17.345 7.924 l
-14.364 -1.252 l
h
-25.805 -12.253 31.616 31.616 re
-25.805 19.363 m
f
Q
q 1 0 0 1 125.1715 70.7154 cm
0 0 m
-0.054 1.185 -0.123 2.614 -0.109 3.853 c
-0.15 3.853 l
-0.449 2.736 -0.831 1.498 -1.239 0.34 c
-2.587 -3.635 l
-3.866 -3.635 l
-5.092 0.286 l
-5.446 1.457 -5.772 2.709 -6.018 3.853 c
-6.045 3.853 l
-6.086 2.655 -6.14 1.198 -6.208 -0.055 c
-6.413 -3.744 l
-7.978 -3.744 l
-7.365 5.432 l
-5.16 5.432 l
-3.962 1.743 l
-3.635 0.667 -3.349 -0.422 -3.118 -1.443 c
-3.077 -1.443 l
-2.832 -0.449 -2.519 0.681 -2.165 1.756 c
-0.899 5.432 l
1.28 5.432 l
1.811 -3.744 l
0.177 -3.744 l
h
f
Q
q 1 0 0 1 132.7822 70.9877 cm
0 0 m
0.014 0.613 -0.259 1.62 -1.375 1.62 c
-2.41 1.62 -2.846 0.681 -2.914 0 c
h
-2.914 -1.171 m
-2.873 -2.369 -1.947 -2.886 -0.871 -2.886 c
-0.095 -2.886 0.449 -2.764 0.966 -2.587 c
1.211 -3.73 l
0.64 -3.975 -0.15 -4.152 -1.103 -4.152 c
-3.254 -4.152 -4.52 -2.832 -4.52 -0.803 c
-4.52 1.035 -3.404 2.764 -1.28 2.764 c
0.871 2.764 1.579 0.994 1.579 -0.463 c
1.579 -0.776 1.552 -1.021 1.525 -1.171 c
h
f
Q
q 1 0 0 1 140.1476 70.8379 cm
0 0 m
0 0.136 -0.014 0.313 -0.041 0.449 c
-0.191 1.089 -0.721 1.62 -1.484 1.62 c
-2.559 1.62 -3.158 0.667 -3.158 -0.558 c
-3.158 -1.783 -2.559 -2.668 -1.497 -2.668 c
-0.817 -2.668 -0.218 -2.205 -0.054 -1.484 c
-0.014 -1.334 0 -1.171 0 -0.994 c
h
1.675 5.8 m
1.675 -2.001 l
1.675 -2.682 1.702 -3.417 1.729 -3.866 c
0.245 -3.866 l
0.163 -2.818 l
0.136 -2.818 l
-0.259 -3.553 -1.062 -4.016 -2.015 -4.016 c
-3.608 -4.016 -4.86 -2.668 -4.86 -0.626 c
-4.874 1.593 -3.485 2.914 -1.892 2.914 c
-0.98 2.914 -0.327 2.546 -0.027 2.056 c
0 2.056 l
0 5.8 l
h
f
Q
143.619 73.602 1.675 -6.63 re
143.619 66.971 m
145.403 75.453 m
145.403 74.963 145.036 74.555 144.45 74.555 c
143.892 74.555 143.524 74.963 143.524 75.453 c
143.524 75.971 143.906 76.365 144.464 76.365 c
145.036 76.365 145.39 75.971 145.403 75.453 c
f
q 1 0 0 1 150.6175 70.2117 cm
0 0 m
-1.184 0.014 -2.315 -0.231 -2.315 -1.239 c
-2.315 -1.892 -1.892 -2.192 -1.361 -2.192 c
-0.681 -2.192 -0.204 -1.756 -0.041 -1.28 c
0 -1.157 0 -1.035 0 -0.912 c
h
1.634 -1.647 m
1.634 -2.246 1.661 -2.832 1.743 -3.24 c
0.231 -3.24 l
0.109 -2.505 l
0.068 -2.505 l
-0.327 -3.022 -1.021 -3.39 -1.892 -3.39 c
-3.226 -3.39 -3.975 -2.423 -3.975 -1.416 c
-3.975 0.245 -2.492 1.103 -0.041 1.089 c
-0.041 1.198 l
-0.041 1.634 -0.218 2.355 -1.389 2.355 c
-2.042 2.355 -2.723 2.151 -3.172 1.865 c
-3.499 2.954 l
-3.009 3.254 -2.151 3.54 -1.103 3.54 c
1.021 3.54 1.634 2.192 1.634 0.735 c
h
f
Q
Q
/CS0 CS 1 SCN
1 w
/GS1 gs
q 1 0 0 1 36 602.7495 cm
0 0 m
165.984 0 l
S
Q
q 1 0 0 1 36 567.7495 cm
0 0 m
165.984 0 l
S
Q
BT
/GS0 gs
/T1_3 1 Tf
0.01 Tc 9 0 0 9 36 737.0496 Tm
(pimecrolimus\). The yellow zone indi)Tj
0 Tc (-)Tj
0.01 Tc 0 -1.2 TD
[(cates worsening eczema, which calls for)10 ( )]TJ
0 -1.2 TD
(increased dosing of steroids or calcineu)Tj
0 Tc (-)Tj
0.01 Tc 0 -1.2 TD
[(rins. The red zone indicates uncontrolled)10 ( )]TJ
T*
[(eczema, which indicates that clinician)10 ( )]TJ
T*
[(contact is appropriate and a prescription)10 ( )]TJ
0 -1.2 TD
(for stronger corticosteroids is needed.)Tj
0 Tc 0 -1.2 TD
(At this point, action plans for eczema are )Tj
0 -1.2 TD
(a fairly new concept. It is anticipated that )Tj
T*
(such action plans will evolve as we learn )Tj
T*
(more about their ef\037cacy in enhancing pa)Tj
(-)Tj
0 -1.2 TD
(tient self-care and timely consultations. )Tj
/CS0 cs 1 scn
/GS1 gs
/C2_0 1 Tf
10 0 0 10 193.0033 618.2495 Tm
<0084>Tj
0 0 0 1 k
/GS0 gs
/TT0 1 Tf
-0.005 Tc -0.004 Tw 14 0 0 14 36 588.7495 Tm
[(P)17.6 (rophylaxis of Genital Herpes)-5 ( )]TJ
0 Tw 0 -1.143 TD
[(R)17.6 (ecurrences with Antivirals)]TJ
/TT1 1 Tf
0 Tc 9 0 0 9 36 549.9495 Tm
(SOURCE: Sands-Lincoln M, Goldmann DR. )Tj
0 -1.2 TD
(Antiviral drugs to prevent clinical recurrence )Tj
T*
(in patients with genital herpes. )Tj
/TT2 1 Tf
11.764 0 Td
(Am J Med)Tj
/TT1 1 Tf
( )Tj
-11.764 -1.2 Td
(2016;129:1264-1266.)Tj
/TT0 1 Tf
30.3235 0 0 30.3235 33.779 486.9495 Tm
(F)Tj
/T1_3 1 Tf
0.01 Tc 9 0 0 9 49.3329 497.7495 Tm
[(or now)92 (, herpes has outsmarted us.)9.9 ( )]TJ
T*
[(Antivirals can reduce the duration)9.9 ( )]TJ
-1.481 -1.2 Td
[(of acute attacks, decrease the number of)10 ( )]TJ
T*
[(days of viral shedding, and reduce the)10 ( )]TJ
T*
(frequency of recurrences, b)Tj
[(ut they do not)10 ( )]TJ
T*
(eradicate the latent virus or alter the)Tj
[( the)10 ( )]TJ
T*
[(natural course of disease. Once antiviral)10 ( )]TJ
T*
(treatment ends, the frequency and sever)Tj
0 Tc 17.445 0 Td
(-)Tj
0.01 Tc -17.445 -1.2 Td
(ity of attacks resumes unaltered.)Tj
ET
/GS1 gs
q 1 0 0 1 214.008 447.0894 cm
0 0 m
165.984 0 l
S
Q
q 1 0 0 1 214.008 411.9178 cm
0 0 m
165.984 0 l
S
Q
BT
/GS0 gs
9 0 0 9 214.008 737.0496 Tm
[(However)111 (, the good news is that the three)10 ( )]TJ
0 -1.219 TD
[(currently approved antivirals \(acyclovir)111 (,)10 ( )]TJ
T*
[(famciclovir)111 (, valacyclovir\) can produce)10 ( )]TJ
0 -1.219 TD
[(a major)111 (, albeit imperfect, effect on)10 ( )]TJ
0 -1.219 TD
[(recurrences when administered daily)10 ( )]TJ
0 -1.219 TD
[(as prophylaxis. The literature suggests)10 ( )]TJ
0 -1.219 TD
[(recurrences can be reduced by as much)10 ( )]TJ
0 -1.219 TD
[(as 70-80% in patients presenting with)10 ( )]TJ
0 -1.219 TD
(frequent recurrences.)Tj
0 -2.438 TD
[(Long-term data \(one to six years\) support)10 ( )]TJ
0 -1.219 TD
[(the safety and ef\037cacy of the antivirals,)9.9 ( )]TJ
T*
[(each of which has demonstrated similar)10 ( )]TJ
-0.01 Tw T*
[(bene\037t.)10 ( )]TJ
0 Tw 0 -2.438 TD
[(In the absence of head-to-head clinical)10 ( )]TJ
0 -1.219 TD
[(trials, no substantial differences in)9.9 ( )]TJ
T*
[(ef\037cacy or tolerability among the)10.1 ( )]TJ
T*
[(three potential treatments has been)10 ( )]TJ
-0.01 Tw T*
[(demonstrated.)10 ( )]TJ
0 Tw 0 -2.438 TD
[(Our experience with antivirals against)10 ( )]TJ
0 -1.219 TD
[(in\036uenza has taught us that problematic)10 ( )]TJ
0 -1.219 TD
[(levels of resistance can occur quickly)92 (, but)10 ( )]TJ
0 -1.219 TD
[(similar trends for genital herpes have not)10 ( )]TJ
-0.01 Tw 0 -1.219 TD
[(been )-10 (observed. )]TJ
/CS0 cs 1 scn
/GS1 gs
/C2_0 1 Tf
0 Tc 0 Tw 10 0 0 10 277.7813 462.7609 Tm
<0084>Tj
0 0 0 1 k
/GS0 gs
/TT0 1 Tf
-0.005 Tc 14 0 0 14 214.008 433.0894 Tm
[(Atrial Fibrillation Still)-4.9 ( )]TJ
0 Tc 8.455 0 Td
( )Tj
-0.005 Tc -8.455 -1.155 Td
(a Mortal Disorder)Tj
/TT1 1 Tf
0 Tc 9 0 0 9 214.008 393.9463 Tm
[(SOURCE: F)35.8 (auchier L, Villejoubert O)39.8 (, Clementy )]TJ
T*
(N, et al. Causes of death and influencing fac)Tj
16.62 0 Td
(-)Tj
-16.62 -1.219 Td
(tors in patients with atrial fibrillation. )Tj
/TT2 1 Tf
13.846 0 Td
(Am J Med)Tj
/TT1 1 Tf
( )Tj
-13.846 -1.219 Td
(2016;129:1278-1287.)Tj
/TT0 1 Tf
30.3235 0 0 30.3235 213.8007 330.2601 Tm
(T)Tj
/T1_3 1 Tf
0.01 Tc 9 0 0 9 232.686 341.0601 Tm
(he advent of warfarin for anticoagu)Tj
0 Tc (-)Tj
0.01 Tc 0 -1.2 TD
[(lation in patients presenting with)10 ( )]TJ
-2.075 -1.219 Td
[(atrial \037brillation \(AF\) provided dramatic)10 ( )]TJ
0 -1.219 TD
[(risk reductions; more than 60% reduced)10 ( )]TJ
T*
[(risk of ischemic stroke, and more than)10 ( )]TJ
T*
[(25% reduced mortality)92 (. The addition of)10 ( )]TJ
T*
(novel anticoagulants \(factor Xa and anti)Tj
0 Tc (-)Tj
0.01 Tc T*
[(thrombin agents\) reduces risk even more.)10 ( )]TJ
0 Tc 0 -2.438 TD
(It may come as a surprise that of the 5.5% )Tj
0 -1.219 TD
(annual risk of death noted in a population )Tj
T*
(of AF patients, the three most common )Tj
0 -1.219 TD
(causes of death were heart failure \(29%\), )Tj
0 -1.219 TD
(infection \(18%\), and cancer \(12%\).)Tj
0.01 Tc -0.005 Tw 0 -2.438 TD
(Of course, anticoagulation does not total)Tj
0 Tc 0 Tw (-)Tj
0.01 Tc 0 -1.219 TD
[(ly eliminate stroke-related deaths in AF)129 (,)10 ( )]TJ
T*
[(not only because not all strokes may be)10 ( )]TJ
T*
[(caused by other disorders besides AF)129 (, but)10 ( )]TJ
T*
[(also because utilization of anticoagulants,)10 ( )]TJ
T*
[(particularly warfarin, also is imperfect.)10 ( )]TJ
0 -2.438 TD
[(Stroke and bleeding remain less frequent,)9.9 ( )]TJ
0 -1.219 TD
[(but nonetheless important, causes of)10 ( )]TJ
T*
[(death in the AF population studied \(n)10 ( )]TJ
T*
[(= 7,668\), each accountable for 7% of)10 ( )]TJ
-0.01 Tw T*
(deaths.)Tj
ET
/GS1 gs
q 1 0 0 1 392.016 645.9495 cm
0 0 m
165.984 0 l
S
Q
q 1 0 0 1 392.016 594.9495 cm
0 0 m
165.984 0 l
S
Q
BT
/GS0 gs
0 Tw 9 0 0 9 392.016 737.0496 Tm
[(Although we have much to celebrate)10 ( )]TJ
0 -1.2 TD
[(in the ef\037cacy of established and novel)10 ( )]TJ
0 -1.2 TD
[(treatments for stroke prevention in AF)129 (,)10 ( )]TJ
0 -1.2 TD
[(the authors proposed that we might pay)10 ( )]TJ
T*
(greater attention to prevention, identi\037)Tj
0 Tc (-)Tj
0.01 Tc T*
[(cation, and management of heart failure,)10 ( )]TJ
0 -1.2 TD
[(as it is the most frequent cause of death)10 ( )]TJ
0 -1.2 TD
[(in patients presenting with AF)128.9 (. )10 ( )]TJ
/CS0 cs 1 scn
/GS1 gs
/C2_0 1 Tf
0 Tc 10 0 0 10 518.1769 661.4495 Tm
<0084>Tj
0 0 0 1 k
/GS0 gs
/TT0 1 Tf
-0.005 Tc 14 0 0 14 392.016 631.9495 Tm
[(Identifying Risk)-4.9 ( )]TJ
0 Tc 6.205 0 Td
( )Tj
-0.005 Tc -6.205 -1.143 Td
(for Macrovascular Events)Tj
0 Tc 10.038 0 Td
( )Tj
-0.005 Tc -10.038 -1.143 Td
[(in Diabetes P)35.6 (atients)]TJ
/TT1 1 Tf
0 Tc 9 0 0 9 392.016 577.1495 Tm
[(SOURCE: Mohammedi K, W)54.7 (oodward M, )]TJ
0 -1.2 TD
(Zoungas S, et al. Absence of peripheral )Tj
T*
(pulses and risk of major vascular outcomes in )Tj
T*
(patients with type 2 diabetes. )Tj
/TT2 1 Tf
11.378 0 Td
(Diabetes Care)Tj
/TT1 1 Tf
5.275 0 Td
( )Tj
-16.653 -1.2 Td
(2016;39:2270-2277.)Tj
/TT0 1 Tf
30.3235 0 0 30.3235 390.9203 503.3495 Tm
(C)Tj
/T1_3 1 Tf
0.01 Tc 9 0 0 9 412.2634 514.1495 Tm
[(ardiovascular disease is the most)10 ( )]TJ
T*
[(common cause of death for patients)10 ( )]TJ
-2.25 -1.2 Td
[(suffering from type 2 diabetes. Even)10 ( )]TJ
T*
(though it is also common for type 2 dia)Tj
0 Tc (-)Tj
0.01 Tc T*
[(betes patients to suffer from dyslipidemia)10 ( )]TJ
T*
[(and hypertension, the cardiovascular)10 ( )]TJ
T*
[(disease risk is disproportionate to these)10 ( )]TJ
0 Tc T*
[(b)-10 (u)-10 (r)-10 (d)-10 (e)-10 (n)-10 (s)-10 (.)-10 ( )-10 (How might we better identify )]TJ
T*
(type 2 diabetes patients who are at par)Tj
16.67 0 Td
(-)Tj
-16.67 -1.2 Td
(ticularly high risk?)Tj
0.01 Tc 0 -2.4 TD
[(Creators of the ADV)105 (ANCE trial enrolled)10 ( )]TJ
0 -1.2 TD
[(type 2 diabetes patients \(n = 11,120\))10 ( )]TJ
T*
[(and compared tight vs. standard glucose)10 ( )]TJ
T*
(control for cardiovascular disease out)Tj
0 Tc (-)Tj
0.01 Tc T*
[(comes. However)111 (, the authors were unable)10.1 ( )]TJ
T*
[(to con\037rm any macrovascular bene\037t of)10.1 ( )]TJ
T*
(tight control.)Tj
0 -2.4 TD
[(At enrollment into ADV)105 (ANCE, research)]TJ
0 Tc (-)Tj
0.01 Tc 0 -1.2 TD
[(ers sought and recorded peripheral pulses)10 ( )]TJ
T*
(\(dorsalis pedis and posterior tibial, bilat)Tj
0 Tc (-)Tj
0.01 Tc T*
[(erally\) on physical exam.)9.9 ( )]TJ
0 -2.4 TD
(Over a median of \037ve years of follow-)Tj
0 -1.2 TD
[(up, absence of either pulse predicted)10 ( )]TJ
T*
[(increased risk for myocardial infarction,)10 ( )]TJ
T*
(stroke, cardiovascular death, heart fail)Tj
0 Tc (-)Tj
0.01 Tc T*
[(ure, and all-cause mortality)91.9 (.)10 ( )]TJ
0 -2.4 TD
[(The absence of either of the pulses had)10 ( )]TJ
0 -1.2 TD
[(similar predictive value, and risk of)10 ( )]TJ
T*
[(adversity increased with the number of)10 ( )]TJ
T*
(missing pulses.)Tj
0 -2.4 TD
[(Diabetic patients deserve our best efforts)10 ( )]TJ
0 -1.2 TD
(to prevent, forestall, or mitigate car)Tj
0 Tc 15.658 0 Td
(-)Tj
0.01 Tc -15.658 -1.2 Td
[(diovascular events. The simple clinical)10 ( )]TJ
T*
[(maneuver of peripheral pulse palpation)10 ( )]TJ
T*
[(can help us identify a subgroup of type 2)10 ( )]TJ
T*
[(diabetes patients who are at measurably)10 ( )]TJ
-0.01 Tw T*
[(increased )-10 (risk. )]TJ
/CS0 cs 1 scn
/GS1 gs
/C2_0 1 Tf
0 Tc 0 Tw 10 0 0 10 453.8813 71.3495 Tm
<0084>Tj
ET
endstream
endobj
23 0 obj
<>>>/Subtype/Form>>stream
0 0 0 1 K
3 w 4 M 0 j 0 J
/GS0 gs
q 1 0 0 1 18 754.5 cm
0 0 m
558 0 l
S
Q
endstream
endobj
10 0 obj
<>
endobj
22 0 obj
<>
endobj
24 0 obj
<>stream
application/postscript
AHCmedia(New)_3 tag options_11.8.13
Travis
2014-09-09T14:01:27-04:00
2014-09-09T14:01:27-04:00
2014-09-09T14:01:27-04:00
Adobe Illustrator CC 2014 (Windows)
xmp.iid:bdec626a-762d-6946-8d41-56d8de9e49a7
xmp.did:bdec626a-762d-6946-8d41-56d8de9e49a7
uuid:5D20892493BFDB11914A8590D31508C8
proof:pdf
xmp.iid:13a2ed22-31ef-3e4e-8ae1-9e6a4d59884d
xmp.did:13a2ed22-31ef-3e4e-8ae1-9e6a4d59884d
uuid:5D20892493BFDB11914A8590D31508C8
proof:pdf
converted
from application/pdf to <unknown>
saved
xmp.iid:D27F11740720681191099C3B601C4548
2008-04-17T14:19:15+05:30
Adobe Illustrator CS4
/
converted
from application/pdf to <unknown>
converted
from application/pdf to <unknown>
saved
xmp.iid:F97F1174072068118D4ED246B3ADB1C6
2008-05-15T16:23:06-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FA7F1174072068118D4ED246B3ADB1C6
2008-05-15T17:10:45-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:EF7F117407206811A46CA4519D24356B
2008-05-15T22:53:33-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F07F117407206811A46CA4519D24356B
2008-05-15T23:07:07-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F77F117407206811BDDDFD38D0CF24DD
2008-05-16T10:35:43-07:00
Adobe Illustrator CS4
/
converted
from application/pdf to <unknown>
saved
xmp.iid:F97F117407206811BDDDFD38D0CF24DD
2008-05-16T10:40:59-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to <unknown>
saved
xmp.iid:FA7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:26:55-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FB7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:29:01-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FC7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:29:20-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FD7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:30:54-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FE7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:31:22-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:B233668C16206811BDDDFD38D0CF24DD
2008-05-16T12:23:46-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:B333668C16206811BDDDFD38D0CF24DD
2008-05-16T13:27:54-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:B433668C16206811BDDDFD38D0CF24DD
2008-05-16T13:46:13-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F77F11740720681197C1BF14D1759E83
2008-05-16T15:47:57-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F87F11740720681197C1BF14D1759E83
2008-05-16T15:51:06-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F97F11740720681197C1BF14D1759E83
2008-05-16T15:52:22-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator
saved
xmp.iid:FA7F117407206811B628E3BF27C8C41B
2008-05-22T13:28:01-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator
saved
xmp.iid:FF7F117407206811B628E3BF27C8C41B
2008-05-22T16:23:53-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator
saved
xmp.iid:07C3BD25102DDD1181B594070CEB88D9
2008-05-28T16:45:26-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator
saved
xmp.iid:F87F1174072068119098B097FDA39BEF
2008-06-02T13:25:25-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F77F117407206811BB1DBF8F242B6F84
2008-06-09T14:58:36-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F97F117407206811ACAFB8DA80854E76
2008-06-11T14:31:27-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:0180117407206811834383CD3A8D2303
2008-06-11T22:37:35-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F77F117407206811818C85DF6A1A75C3
2008-06-27T14:40:42-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:2759AC6B4FA8E211B099CEB363CBA397
2013-04-18T13:43:03-04:00
Adobe Illustrator CS4
/
saved
xmp.iid:5E11DEB5A8216811822A8C4A5BB13D00
2014-01-03T17:39:31-05:00
Adobe Illustrator CS6 (Macintosh)
/
converted
from application/postscript to application/vnd.adobe.illustrator
saved
xmp.iid:13a2ed22-31ef-3e4e-8ae1-9e6a4d59884d
2014-01-06T10:41:10-05:00
Adobe Illustrator CC (Windows)
/
converted
from application/postscript to application/vnd.adobe.illustrator
saved
xmp.iid:bdec626a-762d-6946-8d41-56d8de9e49a7
2014-09-09T14:01:27-04:00
Adobe Illustrator CC 2014 (Windows)
/
Print
False
False
1
3.584901
1.584901
Inches
Black
Default Swatch Group
0
White
CMYK
PROCESS
0.000000
0.000000
0.000000
0.000000
Black
CMYK
PROCESS
0.000000
0.000000
0.000000
100.000000
CMYK Red
CMYK
PROCESS
0.000000
100.000000
100.000000
0.000000
CMYK Yellow
CMYK
PROCESS
0.000000
0.000000
100.000000
0.000000
CMYK Green
CMYK
PROCESS
100.000000
0.000000
100.000000
0.000000
CMYK Cyan
CMYK
PROCESS
100.000000
0.000000
0.000000
0.000000
CMYK Blue
CMYK
PROCESS
100.000000
100.000000
0.000000
0.000000
CMYK Magenta
CMYK
PROCESS
0.000000
100.000000
0.000000
0.000000
C=15 M=100 Y=90 K=10
CMYK
PROCESS
15.000000
100.000000
90.000000
10.000000
C=0 M=90 Y=85 K=0
CMYK
PROCESS
0.000000
90.000000
85.000000
0.000000
C=0 M=80 Y=95 K=0
CMYK
PROCESS
0.000000
80.000000
95.000000
0.000000
C=0 M=50 Y=100 K=0
CMYK
PROCESS
0.000000
50.000000
100.000000
0.000000
C=0 M=35 Y=85 K=0
CMYK
PROCESS
0.000000
35.000000
85.000000
0.000000
C=5 M=0 Y=90 K=0
CMYK
PROCESS
5.000000
0.000000
90.000000
0.000000
C=20 M=0 Y=100 K=0
CMYK
PROCESS
20.000000
0.000000
100.000000
0.000000
C=50 M=0 Y=100 K=0
CMYK
PROCESS
50.000000
0.000000
100.000000
0.000000
C=75 M=0 Y=100 K=0
CMYK
PROCESS
75.000000
0.000000
100.000000
0.000000
C=85 M=10 Y=100 K=10
CMYK
PROCESS
85.000000
10.000000
100.000000
10.000000
C=90 M=30 Y=95 K=30
CMYK
PROCESS
90.000000
30.000000
95.000000
30.000000
C=75 M=0 Y=75 K=0
CMYK
PROCESS
75.000000
0.000000
75.000000
0.000000
C=80 M=10 Y=45 K=0
CMYK
PROCESS
80.000000
10.000000
45.000000
0.000000
C=70 M=15 Y=0 K=0
CMYK
PROCESS
70.000000
15.000000
0.000000
0.000000
C=85 M=50 Y=0 K=0
CMYK
PROCESS
85.000000
50.000000
0.000000
0.000000
C=100 M=95 Y=5 K=0
CMYK
PROCESS
100.000000
95.000000
5.000000
0.000000
C=100 M=100 Y=25 K=25
CMYK
PROCESS
100.000000
100.000000
25.000000
25.000000
C=75 M=100 Y=0 K=0
CMYK
PROCESS
75.000000
100.000000
0.000000
0.000000
C=50 M=100 Y=0 K=0
CMYK
PROCESS
50.000000
100.000000
0.000000
0.000000
C=35 M=100 Y=35 K=10
CMYK
PROCESS
35.000000
100.000000
35.000000
10.000000
C=10 M=100 Y=50 K=0
CMYK
PROCESS
10.000000
100.000000
50.000000
0.000000
C=0 M=95 Y=20 K=0
CMYK
PROCESS
0.000000
95.000000
20.000000
0.000000
C=25 M=25 Y=40 K=0
CMYK
PROCESS
25.000000
25.000000
40.000000
0.000000
C=40 M=45 Y=50 K=5
CMYK
PROCESS
40.000000
45.000000
50.000000
5.000000
C=50 M=50 Y=60 K=25
CMYK
PROCESS
50.000000
50.000000
60.000000
25.000000
C=55 M=60 Y=65 K=40
CMYK
PROCESS
55.000000
60.000000
65.000000
40.000000
C=25 M=40 Y=65 K=0
CMYK
PROCESS
25.000000
40.000000
65.000000
0.000000
C=30 M=50 Y=75 K=10
CMYK
PROCESS
30.000000
50.000000
75.000000
10.000000
C=35 M=60 Y=80 K=25
CMYK
PROCESS
35.000000
60.000000
80.000000
25.000000
C=40 M=65 Y=90 K=35
CMYK
PROCESS
40.000000
65.000000
90.000000
35.000000
C=40 M=70 Y=100 K=50
CMYK
PROCESS
40.000000
70.000000
100.000000
50.000000
C=50 M=70 Y=80 K=70
CMYK
PROCESS
50.000000
70.000000
80.000000
70.000000
PANTONE 288 U
SPOT
100.000000
CMYK
100.000000
67.000002
0.000000
23.000000
PANTONE 313 C
SPOT
100.000000
CMYK
100.000000
0.000000
8.000200
13.000500
PANTONE 313 U
SPOT
100.000000
CMYK
100.000000
0.000000
8.000000
13.000000
PANTONE 187 U
SPOT
100.000000
CMYK
0.000000
100.000000
78.999299
19.999699
PANTONE 309 U
SPOT
100.000000
CMYK
100.000000
0.000000
8.999600
72.000098
Grays
1
C=0 M=0 Y=0 K=100
CMYK
PROCESS
0.000000
0.000000
0.000000
100.000000
C=0 M=0 Y=0 K=90
CMYK
PROCESS
0.000000
0.000000
0.000000
89.999400
C=0 M=0 Y=0 K=80
CMYK
PROCESS
0.000000
0.000000
0.000000
79.998800
C=0 M=0 Y=0 K=70
CMYK
PROCESS
0.000000
0.000000
0.000000
69.999700
C=0 M=0 Y=0 K=60
CMYK
PROCESS
0.000000
0.000000
0.000000
59.999100
C=0 M=0 Y=0 K=50
CMYK
PROCESS
0.000000
0.000000
0.000000
50.000000
C=0 M=0 Y=0 K=40
CMYK
PROCESS
0.000000
0.000000
0.000000
39.999400
C=0 M=0 Y=0 K=30
CMYK
PROCESS
0.000000
0.000000
0.000000
29.998800
C=0 M=0 Y=0 K=20
CMYK
PROCESS
0.000000
0.000000
0.000000
19.999700
C=0 M=0 Y=0 K=10
CMYK
PROCESS
0.000000
0.000000
0.000000
9.999100
C=0 M=0 Y=0 K=5
CMYK
PROCESS
0.000000
0.000000
0.000000
4.998800
Brights
1
C=0 M=100 Y=100 K=0
CMYK
PROCESS
0.000000
100.000000
100.000000
0.000000
C=0 M=75 Y=100 K=0
CMYK
PROCESS
0.000000
75.000000
100.000000
0.000000
C=0 M=10 Y=95 K=0
CMYK
PROCESS
0.000000
10.000000
95.000000
0.000000
C=85 M=10 Y=100 K=0
CMYK
PROCESS
85.000000
10.000000
100.000000
0.000000
C=100 M=90 Y=0 K=0
CMYK
PROCESS
100.000000
90.000000
0.000000
0.000000
C=60 M=90 Y=0 K=0
CMYK
PROCESS
60.000000
90.000000
0.003100
0.003100
Adobe PDF library 10.01
endstream
endobj
11 0 obj
<>
endobj
19 0 obj
<>
endobj
20 0 obj
<>
endobj
21 0 obj
<>
endobj
12 0 obj
<>
endobj
13 0 obj
<>
endobj
15 0 obj
<>
endobj
16 0 obj
<>
endobj
40 0 obj
<>
endobj
41 0 obj
<>stream
HdNV{q)>J\> i\?m 6eȷ<O/fst]~x{_Nϯ7ww˛oxx2r/?2އp?D??yz{qfzOt:m-_7͆"uDsF'OuOD'&2G'j~"7vG?j$O ?O'I?ɟ'$O ?O'I?ɟ'3,Ɵ?gYyV2ee*)U,S,XXVLbbY2Ų++*V(VTPXXQBbbE
ŊnL_//?R_/WU_W+*_WU_W+*_o7M7&o
o7M7&o
:zX.oز>*+zR9OS Mb
endstream
endobj
42 0 obj
<>stream
HtU TSW['}MqRDQ)jYCDkqkZZHJ-ju\pV-
=ͨ0{w ;,i3CҾ!]{ 63r+T+I֢/]0@I.F'
](!}d> e@ à²*3Oli$<ŧ'{¼qً Ee6Y_ 8qQyA8A~9s!288b甕A81ֲG$,j'By/R(ʬml
GJ88haCBô#"FF=f_^y=v\ 'M05qZ3Hy35-Yogdfe#'W?gE%J+*Yn͢K.{XծY>Xi
6~mMk/~u7ࡶGz8yt_ݥ_z퇎7nw=x# ,I0flV9?
PFv5G3T3Q9g2kmLle,|k,w$h/qf/L&O?DLLsLN=X kYr~&p`$C-\KVQb-s,dZN8:<X{D>6t_&i?шf|8 wy\\e|C\5|xq|`bm(B (G*P_PwPhv,,RGN1B{#?n!p#i>oqe8/y`܂go_X;N$yt\/Etl!}IxzB`>#q:O+g! 20@Ϭ.:0KhQ. є>h``:²EیxKgєR]UCE)JBXT\/*ͼᢑĚJ"U<]7:*>.Qox5(['Jv]Z$R.iƚQ.5blJHh絰&\A0Wl~5,4EH|%֔.i
BˁJ>J)eB~n {Y>4νf/F*crt1SURU+ZUm&SR)^U{gʇæ$Zo:>+d3SiiHLqtu^lSY
{N&7dzaw:
JZVKyG:H(Je(UepM!XK!Aъh0
)Tjx0[u%Xoc/42:O$L_gPv:eX&d&zb"1&V!ݎ
_o/OwWg'B`ogkc%{Uk7mǴk;nj1hw-PJyTm!?;ݹnPshb},Vc-},Ig
[c^ogFtt#{jtκd/_/>\#15A2RfYoUFFlĀ`g/'&hHFE)Lik5Z6'NETPH\#"nQ..ʀQQRb$]()M^`i:mk4>>.Ot8϶<98/ĺyF7w愍i*K**S#yq}ᒺVTZ$I+<pLng:guύpxyH ؊Q#ԑ=ާ
3zBn$%\kKZ3,?Mٟ;wkljl\؟ldWPT}?*ـ]Y@@֭Q
E bU5(DQ%LuiElmfkI+$`&aar;wNSZOGC{
`C7>KW:ΎƀnuY'
eH&TM4]4UpH=4'RTKZrӠ8Өibٱo[
kfM=X2~z.Me*x'S2c7n?g'+m}pdd4ߔcFT lZ!xo!F#i"̢Xb](8Ĉ'az?"I@ؑ(hЫ&Aa<%ҩ#0-Z1ܠL: { >:̨Լ2IHўġ+ ')aE"X1W0|$IոB^ttWJU8n8ROjp#\go1$he{,2^xX:VQZc{zO_:MKL6 ڒl&ZIϳw9ؖBRsHDMvF
"uU
it}lO}RȍYǺ'\`Yzp#"jsWU ?4Sl
Ff 2HtHlC):]ʑ),YZeCŔ7.:@|wgwN3 E1ng0!?FU1]ŝa)Щf1(X&NI6COϛ@%Ebnʫ5f6-g.߱j%iUo0.ؿYj>usҟcAҫpj96g7-P+3_%#Dj>Q"#VTc@V@h>1ϲٰ>i`ޙ}_~@A?7yn_-Րe+-KVvaQ5@bEofz?6ES1C
:@G,<)p#<7\^(]4e݆fUTʩu9)՞H^zR[]ݶ~L/48]
T:y
K@yTWRVxU^hDq\]ԥ&%˅ӂ797;NʂWhiߩZJ`qxHqGEF'r>1/G-^93b@QP&RjdȆzdAXiذ*(Ώߋ?!JI#&Dܕ\тlO9e4kp;?_f!C]pǯ4p*j2f59Xo n!=ò%+%u']'_+;yCO\oV:-{f4fT͇'x>GX7ȣn pV Tz%Jmyl^H .f#Jw>ExT3Ƣj ZjWBlgeԆ[b>#Bq{Gj3]7+'(ӻڶݭ{7חT·6DY:8 *-RG@6UPR 3h{%Ҥ)#uFGXuWHKp?5*댞s
30R")E hFDYUEUc4˷֨52Y\j
4Ƙ$tܹh\39E%" Q
s_fW
\r[NԜn,@ n;y4jjgȃ+i[,